Menu
1 min read · estimated
APPROVED USE
What FDA approved
Adults with locally advanced or metastatic nonsquamous NSCLC with an activating HER2 (ERBB2) tyrosine kinase domain mutation on an FDA-authorized test. The expanded label removes the prior systemic-treatment requirement.
LAMPGEN ANALYSIS
Why it matters
The new label broadens an existing accelerated indication to include patients without prior systemic therapy. HER2 kinase-domain mutations define the population.
What research teams should watch
Reconcile HER2 mutation class, stage and earlier therapy in the screening record. Follow the confirmatory study and avoid equating response in a single-arm cohort with comparative survival benefit.
PRIMARY RECORDS